Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Embecta Corp.
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move will be running to a monthly schedule from now, with this edition covering medtech's executive changes for April.
Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.
- Infusion Therapy Equipment and Supplies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.